文献速递泌尿生殖MR

磁共振指纹成像与扩散成像对外周带前列腺癌特征的前瞻性靶向活检验证

Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping.
PubMed 文献 · Invest Radiol · 2019-01-01

回顾性分析85例患者104个外周带病灶,以靶向活检为参考标准,评估磁共振指纹成像(MRF)的T1、T2弛豫时间与ADC图对外周带前列腺癌与非癌病变的鉴别价值。结果显示前列腺癌的T1、T2、ADC均显著低于前列腺炎和阴性活检,T1+ADC鉴别癌与阴性活检的AUC为0.83,T2+ADC鉴别低级别与临床显著癌的AUC为0.91。

要点

  • 前列腺癌T1、T2、ADC均显著低于前列腺炎和阴性活检。
  • T1+ADC鉴别癌与阴性活检的AUC为0.83,为最佳组合。
  • T2+ADC鉴别低级别与临床显著癌的AUC为0.91,为最佳组合。

核心结论

  • T1和T2弛豫时间联合ADC图可能有助于外周带前列腺癌的定量分级及与前列腺炎、阴性活检的鉴别。

研究设计与样本

  • 回顾性分析85例患者104个外周带病灶,均行MRI(ADC图、MRF)及靶向活检(认知融合或磁共振引导下),由对病理不知情的放射科医生在MRF和ADC图上勾画靶病灶及视觉正常外周带感兴趣区。

关键影像表现/征象

  • 前列腺癌T1为1660±270毫秒、T2为56±20毫秒、ADC为0.70×10±0.24×10 mm/s,均显著低于前列腺炎(T1 1730±350毫秒、T2 77±36毫秒、ADC 1.00×10±0.30×10 mm/s)和阴性活检(T1 1810±250毫秒、T2 71±37毫秒、ADC 1.00×10±0.33×10 mm/s)。

诊断标准与关键数值

  • 癌与前列腺炎鉴别:ADC敏感、T2特异,AUC_T2=0.71、AUC_ADC=0.79,两者AUC差异无统计学意义(P=0.37)。癌与阴性活检鉴别:T1+ADC的AUC_T1+ADC=0.83,为最佳分离。低级别癌与临床显著癌鉴别:低级别癌T2为75±29毫秒、ADC为0.96×10±0.34×10 mm/s,显著高于临床显著癌(T2 52±16毫秒、ADC 0.65±0.18×10 mm/s),T2+ADC的AUC_T2+ADC=0.91,为最佳分离。

临床应用与阅片要点

  • 对外周带T2加权图像上可见的病灶,可结合MRF测量的T1、T2弛豫时间与ADC图进行定量分析,辅助区分前列腺癌、前列腺炎与阴性活检,并可能帮助区分低级别与临床显著癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study aims for targeted biopsy validation of magnetic resonance fingerprinting (MRF) and diffusion mapping for characterizing peripheral zone (PZ) prostate cancer and noncancers.

MATERIALS AND METHODS: One hundred four PZ lesions in 85 patients who underwent magnetic resonance imaging were retrospectively analyzed with apparent diffusion coefficient (ADC) mapping, MRF, and targeted biopsy (cognitive or in-gantry). A radiologist blinded to pathology drew regions of interest on targeted lesions and visually normal peripheral zone on MRF and ADC maps. Mean T1, T2, and ADC were analyzed using linear mixed models. Generalized estimating equations logistic regression analyses were used to evaluate T1 and T2 relaxometry combined with ADC in differentiating pathologic groups.

RESULTS: Targeted biopsy revealed 63 cancers (low-grade cancer/Gleason score 6 = 10, clinically significant cancer/Gleason score ≥7 = 53), 15 prostatitis, and 26 negative biopsies. Prostate cancer T1, T2, and ADC (mean ± SD, 1660 ± 270 milliseconds, 56 ± 20 milliseconds, 0.70 × 10 ± 0.24 × 10 mm/s) were significantly lower than prostatitis (mean ± SD, 1730 ± 350 milliseconds, 77 ± 36 milliseconds, 1.00 × 10 ± 0.30 × 10 mm/s) and negative biopsies (mean ± SD, 1810 ± 250 milliseconds, 71 ± 37 milliseconds, 1.00 × 10 ± 0.33 × 10 mm/s). For cancer versus prostatitis, ADC was sensitive and T2 specific with comparable area under curve (AUC; (AUCT2 = 0.71, AUCADC = 0.79, difference between AUCs not significant P = 0.37). T1 + ADC (AUCT1 + ADC = 0.83) provided the best separation between cancer and negative biopsies. Low-grade cancer T2 and ADC (mean ± SD, 75 ± 29 milliseconds, 0.96 × 10 ± 0.34 × 10 mm/s) were significantly higher than clinically significant cancers (mean ± SD, 52 ± 16 milliseconds, 0.65 ± 0.18 × 10 mm/s), and T2 + ADC (AUCT2 + ADC = 0.91) provided the best separation.

CONCLUSIONS: T1 and T2 relaxometry combined with ADC mapping may be useful for quantitative characterization of prostate cancer grades and differentiating cancer from noncancers for PZ lesions seen on T2-weighted images.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Panda A, OʼConnor G, Lo WC, et al. Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping. Invest Radiol. 2019. PMID: 30985480. doi:10.1097/RLI.0000000000000569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。